{"meta":{"query_hash":"fe933d0e8be0","filters":{"venue":"Therapeutic Advances in Hematology"},"cohort_total":20,"direct_labels_cover":0,"predictions_cover":20,"exported":20,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/fe933d0e8be0","api":"https://metacan.xera.ac/api/v1/cohort?venue=Therapeutic+Advances+in+Hematology"},"results":[{"id":"W2102216347","doi":"10.1177/2040620712453067","title":"Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism","year":2012,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Hamilton General Hospital","funders":"Bayer HealthCare","keywords":"Medicine; Rivaroxaban; Dabigatran; Apixaban; Edoxaban; Deep vein; Pulmonary embolism; Atrial fibrillation; Thrombosis; Intensive care medicine; Warfarin; Surgery; Internal medicine","score_opus":0.030524975829067942,"score_gpt":0.3507486128392116,"score_spread":0.32022363701014367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102216347","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030969959,0.9338341,0.0026136362,0.0487616,0.0025170308,0.000019225668,0.000056092347,0.000031059517,0.009070251],"genre_scores_gemma":[0.034749966,0.9351791,0.004897817,0.010417315,0.011707861,0.000026278578,0.00006672685,0.000020542742,0.002934407],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99791986,0.00084246387,0.00023336185,0.00016238434,0.0007743508,0.00006753698],"domain_scores_gemma":[0.99615866,0.0016786674,0.00042241573,0.00023088645,0.001249145,0.00026025096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005622409,0.00050556497,0.00070377626,0.00091636257,0.00039299243,0.0018517888,0.00058106316,0.001504541,0.0047559175],"category_scores_gemma":[0.0067996345,0.00015604157,0.00039802995,0.0010786272,0.0010243712,0.0023513674,0.00079124,0.0032120005,0.0017820616],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032744868,0.0002752946,0.0014074203,0.0017405793,0.00007355979,0.0001798281,0.00010535738,0.0003270966,0.0016525224,0.012868072,0.03229204,0.9487508],"study_design_scores_gemma":[0.0002211152,0.00070828834,0.006551952,0.0026197163,0.00022531938,0.002358623,0.0001690322,0.00077815034,0.0022064862,0.019105455,0.9650105,0.000045315905],"about_ca_topic_score_codex":0.0012380654,"about_ca_topic_score_gemma":0.0013426552,"teacher_disagreement_score":0.005622409,"about_ca_system_score_codex":0.0009338394,"about_ca_system_score_gemma":0.0017557582,"threshold_uncertainty_score":0.029734433},"labels":[],"label_agreement":null},{"id":"W2122059243","doi":"10.1177/2040620715571077","title":"Targeting polo-like kinase 1 in acute myeloid leukemia","year":2015,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"PLK1; Medicine; Cytarabine; Myeloid leukemia; Leukemia; Polo-like kinase; Myeloid; Clinical trial; Oncology; Cancer research; Internal medicine; Cell cycle; Pharmacology; Cancer","score_opus":0.053688199064231314,"score_gpt":0.4039952893888705,"score_spread":0.3503070903246392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122059243","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016340049,0.9987406,0.000062812505,0.00013374098,0.000099162804,0.000005940747,0.00001610937,0.0000055305927,0.0007727172],"genre_scores_gemma":[0.0006768238,0.9984877,0.00010430483,0.00014359377,0.0000577613,0.000005379626,0.00003362462,0.0000010395953,0.00048971636],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987924,0.000018942032,0.000019415693,0.00001907422,0.00005081886,0.0000125529405],"domain_scores_gemma":[0.99988043,0.00004412118,0.000027038983,0.0000033008273,0.00003153839,0.000013479177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039521692,0.00054718193,0.0010632079,0.0019552808,0.00019580478,0.00065563695,0.00069654826,0.00059351715,0.0036946568],"category_scores_gemma":[0.00039195508,0.00022642378,0.0004932802,0.0015598617,0.00025557427,0.00091862754,0.00059395406,0.0013525847,0.0020884105],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000091904505,0.000072572984,0.00013653543,0.021063613,0.00011584341,0.00017978936,0.00005108227,0.00027621211,0.002235463,0.0019820181,0.02369127,0.9501036],"study_design_scores_gemma":[0.000037612324,0.0001193926,0.0006597836,0.0034411247,0.00015816845,0.0012108901,0.00003930615,0.000075666016,0.0005306396,0.0011644762,0.9925494,0.000013572899],"about_ca_topic_score_codex":0.00064875063,"about_ca_topic_score_gemma":0.0015939479,"teacher_disagreement_score":0.0036946568,"about_ca_system_score_codex":0.00036962188,"about_ca_system_score_gemma":0.00059501815,"threshold_uncertainty_score":0.012359858},"labels":[],"label_agreement":null},{"id":"W2160410546","doi":"10.1177/2040620712471553","title":"The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update","year":2013,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Alberta Cancer Foundation","keywords":"Anaplastic lymphoma kinase; Cancer research; Carcinogenesis; Anaplastic large-cell lymphoma; Tyrosine kinase; STAT protein; Signal transduction; STAT3; Biology; Medicine; Lymphoma; Cell biology; Cancer; Pathology; Immunology; Internal medicine; Lung cancer","score_opus":0.01015474149840613,"score_gpt":0.2801749200807791,"score_spread":0.270020178582373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160410546","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00070133805,0.99415237,0.0005208468,0.001235033,0.0020473527,0.000006600542,0.000053890115,0.000023356206,0.0012592516],"genre_scores_gemma":[0.002177261,0.98874027,0.0006640455,0.001122213,0.006119989,0.000011542364,0.00014398285,0.000005552772,0.0010151019],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998473,0.000024113231,0.000035020297,0.000036649122,0.00003835345,0.000018485718],"domain_scores_gemma":[0.99956566,0.0001845889,0.00007434589,0.000012906448,0.00011057419,0.00005192269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004522307,0.0010185,0.0011914065,0.0028361226,0.00028052373,0.0011972449,0.0007449939,0.0014954916,0.002984585],"category_scores_gemma":[0.00067129475,0.00033505933,0.00059625035,0.0016798595,0.0005147905,0.0022747675,0.0006446753,0.0021491968,0.0016974815],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003234736,0.00018938318,0.0015380402,0.016311903,0.00016990192,0.003198909,0.0001789815,0.0006278622,0.009091503,0.0048574377,0.101447865,0.8620647],"study_design_scores_gemma":[0.000013551551,0.00017907242,0.0015909966,0.0017876127,0.00018510951,0.010878333,0.00010838175,0.00020780906,0.0010242915,0.0017554086,0.98223037,0.00003900326],"about_ca_topic_score_codex":0.00071543833,"about_ca_topic_score_gemma":0.0010437409,"teacher_disagreement_score":0.002984585,"about_ca_system_score_codex":0.0006492727,"about_ca_system_score_gemma":0.0007867695,"threshold_uncertainty_score":0.009984434},"labels":[],"label_agreement":null},{"id":"W2168385579","doi":"10.1177/2040620715586528","title":"Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective","year":2015,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"","keywords":"Obinutuzumab; Medicine; Rituximab; Fludarabine; Chronic lymphocytic leukemia; Oncology; Internal medicine; Chemotherapy; Cyclophosphamide; Leukemia; Venetoclax; Immunology; Lymphoma","score_opus":0.06151108374895914,"score_gpt":0.40383932520121707,"score_spread":0.34232824145225793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168385579","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008678668,0.99929655,0.00004167479,0.0001771578,0.00007481458,0.0000022557253,0.000007141618,0.0000032719104,0.0003102315],"genre_scores_gemma":[0.00050065806,0.99899656,0.0000913268,0.00014530959,0.0000974363,0.000003479183,0.000016154258,7.3537416e-7,0.00014846738],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982697,0.000035858393,0.000029961151,0.000030280058,0.000058785976,0.000018230836],"domain_scores_gemma":[0.9996828,0.00015250086,0.00005194809,0.0000058942387,0.00007694112,0.000029922969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006365445,0.00067322294,0.0011476098,0.0022848828,0.00021322639,0.0006918118,0.0007929704,0.00091358554,0.0021919112],"category_scores_gemma":[0.0006690632,0.00023445034,0.00062067865,0.0015675401,0.0003335423,0.00090338354,0.00046132717,0.0016962966,0.0009991113],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012475648,0.000077716635,0.0002136249,0.017329207,0.00013957998,0.00020117947,0.000058590806,0.00027734978,0.0010060777,0.001745111,0.022025473,0.9568013],"study_design_scores_gemma":[0.00007026518,0.0002513391,0.0014373425,0.009899175,0.00034029275,0.0028154242,0.000076276934,0.00015653488,0.00045957774,0.001861803,0.9826057,0.00002633432],"about_ca_topic_score_codex":0.00093860994,"about_ca_topic_score_gemma":0.002149395,"teacher_disagreement_score":0.0022848828,"about_ca_system_score_codex":0.00051847345,"about_ca_system_score_gemma":0.0007351594,"threshold_uncertainty_score":0.007332623},"labels":[],"label_agreement":null},{"id":"W2756236937","doi":"10.1177/2040620717729128","title":"Red cell genotyping precision medicine: a conference summary","year":2017,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Blood groups and transfusion","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Héma-Québec","funders":"NIH Clinical Center; U.S. Department of Health and Human Services; National Institutes of Health; Grifols; Australian Government; Canadian Blood Services","keywords":"Genotyping; Precision medicine; Medicine; Clinical Practice; Medical physics; Family medicine; Pathology; Genotype; Genetics; Biology","score_opus":0.12555192463188275,"score_gpt":0.4248344417129931,"score_spread":0.29928251708111037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756236937","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011351181,0.98399353,0.00036890636,0.005911394,0.0061124754,0.000031597505,0.00008128113,0.000026927702,0.003360355],"genre_scores_gemma":[0.0005909116,0.99061114,0.00046164377,0.002879066,0.0032580562,0.000029154697,0.00014199119,0.000007323387,0.002020722],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99914217,0.000161883,0.00016066243,0.000110006076,0.00035557617,0.00006971763],"domain_scores_gemma":[0.998083,0.00066177343,0.00019520223,0.000042016185,0.0008500476,0.00016801874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024767204,0.0011033267,0.0010782717,0.0035745318,0.0005380359,0.0020941962,0.001087849,0.0021730422,0.008093217],"category_scores_gemma":[0.0037884815,0.00040186665,0.00083926035,0.003243621,0.0004916766,0.0027987382,0.001481554,0.003505755,0.0048926156],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006408828,0.00006132973,0.00017583188,0.020001628,0.00007807234,0.000436337,0.00015639765,0.00028074204,0.00096892635,0.0065061497,0.27423856,0.6970319],"study_design_scores_gemma":[0.00000532468,0.000026595715,0.00018798251,0.005011997,0.000035801997,0.0005932708,0.000042503238,0.000024887835,0.00015185153,0.00076837646,0.99313825,0.000013169137],"about_ca_topic_score_codex":0.0011984092,"about_ca_topic_score_gemma":0.0019239655,"teacher_disagreement_score":0.008093217,"about_ca_system_score_codex":0.0012355703,"about_ca_system_score_gemma":0.0034995368,"threshold_uncertainty_score":0.027074456},"labels":[],"label_agreement":null},{"id":"W3034142645","doi":"10.1177/2040620720914490","title":"PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Context (archaeology); Oncology; Hodgkin lymphoma; Interim; Regimen; Lymphoma; Internal medicine; Radiation therapy; Clinical trial; Toxicity; Stage (stratigraphy); Medical physics","score_opus":0.15720279791341157,"score_gpt":0.369600646188655,"score_spread":0.21239784827524344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034142645","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001026092,0.9991991,0.000057335074,0.00008215972,0.000063179956,0.0000074191116,0.0000141174805,0.0000038412654,0.00047029625],"genre_scores_gemma":[0.00064161624,0.9989085,0.00012927166,0.00011098553,0.000035740686,0.0000067350124,0.000024140038,8.2351596e-7,0.00014215124],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9998123,0.000048954997,0.000036425325,0.00003309663,0.000054257584,0.000015010381],"domain_scores_gemma":[0.9996954,0.00018752618,0.000047213794,0.000008984652,0.00004633708,0.000014521576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005706743,0.0006429456,0.0013404354,0.0020280464,0.00018747075,0.0006695945,0.0006535025,0.00052226515,0.004296835],"category_scores_gemma":[0.0008533111,0.00017149713,0.00081726554,0.0017355831,0.00028241723,0.0006990766,0.00048552337,0.0012097268,0.0012318246],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011088174,0.00006887438,0.00009848539,0.044531237,0.0002216454,0.0000965144,0.000043359098,0.00027015497,0.0010361536,0.0012651602,0.010040773,0.9422168],"study_design_scores_gemma":[0.00009248699,0.00034765244,0.0019712294,0.024704015,0.0009340392,0.0018947286,0.000101464575,0.00014385929,0.000763682,0.0016772014,0.967344,0.000025700128],"about_ca_topic_score_codex":0.0008225693,"about_ca_topic_score_gemma":0.0021395872,"teacher_disagreement_score":0.004296835,"about_ca_system_score_codex":0.000426772,"about_ca_system_score_gemma":0.0007400058,"threshold_uncertainty_score":0.014374375},"labels":[],"label_agreement":null},{"id":"W3094234317","doi":"10.1177/2040620720966137","title":"One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study","year":2020,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"European Hematology Association; Alexion Pharmaceuticals","keywords":"Eculizumab; Paroxysmal nocturnal hemoglobinuria; Medicine; Internal medicine; Immunology; Antibody; Complement system","score_opus":0.03983949947990802,"score_gpt":0.32467929945707896,"score_spread":0.28483979997717096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094234317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964857,0.0012910049,0.0002955196,0.0001314152,0.00009938357,0.0009403743,0.00035334475,0.000037672355,0.000365576],"genre_scores_gemma":[0.99548703,0.0006776845,0.00067296915,0.00031680646,0.0002828472,0.0012128947,0.0007411264,0.000009646781,0.00059902115],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979717,0.0010703971,0.00018251331,0.00035677353,0.00018627288,0.00023235509],"domain_scores_gemma":[0.9963122,0.00096482795,0.0010943833,0.0005088598,0.00030699253,0.0008127572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005105282,0.0017287132,0.0029352964,0.00055915985,0.0005784547,0.00117099,0.00077329314,0.0017886355,0.0027268142],"category_scores_gemma":[0.0039437506,0.0007669499,0.0032009508,0.00039420303,0.0010348014,0.0013697402,0.0005319833,0.002868203,0.00067849463],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9589591,0.017062007,0.003860617,0.0002084915,0.0013530274,0.0000619125,0.00009939599,0.00026597717,0.002627085,0.000037136113,0.0003278818,0.015137242],"study_design_scores_gemma":[0.73616076,0.24563813,0.014915797,0.000030135887,0.0011475775,0.00009370266,0.00003105303,0.00055293296,0.0008239978,0.00007979167,0.00049541437,0.000030628882],"about_ca_topic_score_codex":0.00075689435,"about_ca_topic_score_gemma":0.0009853687,"teacher_disagreement_score":0.005105282,"about_ca_system_score_codex":0.0008846485,"about_ca_system_score_gemma":0.0010867367,"threshold_uncertainty_score":0.026999652},"labels":[],"label_agreement":null},{"id":"W3094556560","doi":"10.1177/2040620720966888","title":"Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities—a practical review","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Haemophilia; Dosing; Clotting factor; Haemophilia A; Intensive care medicine; Trough level; Population; Pharmacokinetics; Surgery; Internal medicine","score_opus":0.1926136747927358,"score_gpt":0.5560222201151694,"score_spread":0.3634085453224336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094556560","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000611538,0.998628,0.00028834207,0.0004657601,0.00013085705,0.000010403945,0.000016482396,0.0000058507408,0.0003931774],"genre_scores_gemma":[0.00057014416,0.9983376,0.00045946892,0.00022754961,0.00024215464,0.000013572526,0.000020349898,0.0000019031909,0.0001271807],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991084,0.00028344573,0.00017749358,0.00012373937,0.0002667497,0.00004011296],"domain_scores_gemma":[0.9969606,0.0021550409,0.0003044421,0.000060328388,0.00044500994,0.00007462844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023143522,0.0012775516,0.002487857,0.0030198167,0.0003201261,0.0019883446,0.0017317804,0.0021228762,0.0034085957],"category_scores_gemma":[0.004378531,0.00060195953,0.0014326955,0.002728459,0.0010276395,0.0024400745,0.0010486966,0.0024798196,0.001950617],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115490126,0.00013637607,0.00045880594,0.048150845,0.000203835,0.00037268017,0.00016630294,0.0015182064,0.00052088284,0.008674914,0.030647388,0.9090344],"study_design_scores_gemma":[0.000034819812,0.00029246783,0.0018974359,0.03735089,0.00046528096,0.0025513305,0.00018690932,0.0008064021,0.00031535098,0.008144272,0.9478829,0.000071951676],"about_ca_topic_score_codex":0.0021803954,"about_ca_topic_score_gemma":0.0019388867,"teacher_disagreement_score":0.0034085957,"about_ca_system_score_codex":0.0012547832,"about_ca_system_score_gemma":0.0023274312,"threshold_uncertainty_score":0.012239635},"labels":[],"label_agreement":null},{"id":"W3112714545","doi":"10.1177/2040620720977039","title":"Adverse events in second- and third-line treatments for acute and chronic graft- <i>versus</i> -host disease: systematic review","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Extracorporeal Photopheresis; Graft-versus-host disease; Adverse effect; Internal medicine; Incidence (geometry); Hematopoietic stem cell transplantation; Population; Disease; Immunology","score_opus":0.0370342065950142,"score_gpt":0.3841141538634325,"score_spread":0.3470799472684183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112714545","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014729472,0.9974806,0.00009108462,0.00013715998,0.00007016036,0.00015069103,0.00036523998,0.000005440921,0.00022675662],"genre_scores_gemma":[0.03603943,0.96182865,0.0005246447,0.00062062097,0.00010244343,0.00041073427,0.00035369387,0.0000059905847,0.00011373636],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9929404,0.0023259092,0.002941996,0.000471277,0.0011616505,0.00015870074],"domain_scores_gemma":[0.9656681,0.022987412,0.008718136,0.00036236626,0.0020191872,0.00024488047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005555012,0.0010135488,0.005434199,0.005861455,0.000384424,0.0016543872,0.0011075014,0.0012782934,0.0029228344],"category_scores_gemma":[0.030368708,0.0006018792,0.0074617206,0.005409729,0.0006121919,0.001229803,0.000906834,0.00090112555,0.00019517439],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030960827,0.00001519287,0.0016396671,0.9537213,0.013362213,0.00008398278,0.00011216616,0.00010295793,0.00012204422,0.0001258007,0.001259101,0.02914592],"study_design_scores_gemma":[0.0005422814,0.00048787092,0.012883884,0.84440774,0.1196981,0.0008435645,0.00025893905,0.00013318684,0.00028339287,0.00031412183,0.020098913,0.00004813901],"about_ca_topic_score_codex":0.004590831,"about_ca_topic_score_gemma":0.011763843,"teacher_disagreement_score":0.005861455,"about_ca_system_score_codex":0.0019907618,"about_ca_system_score_gemma":0.0046820845,"threshold_uncertainty_score":0.029378116},"labels":[],"label_agreement":null},{"id":"W4226103605","doi":"10.1177/20406207221085202","title":"International consensus recommendations on the management of people with haemophilia B","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"Spark Therapeutics; Genentech; Grifols; Swedish Orphan Biovitrum; Baxalta; CSL Behring; Biogen; Novo Nordisk; Sanofi; Chugai Pharmaceutical; McMaster University; Pfizer","keywords":"Haemophilia; Medicine; Haemophilia B; Haemophilia A; Delphi method; Intensive care medicine; Delphi; Pediatrics","score_opus":0.10476563920737725,"score_gpt":0.423291382229807,"score_spread":0.31852574302242975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226103605","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003115261,0.26748413,0.025013564,0.53605026,0.02709767,0.0075494763,0.008713168,0.000779361,0.12419707],"genre_scores_gemma":[0.04452357,0.45232734,0.2450612,0.15318187,0.0057475325,0.020793675,0.029300395,0.0004306982,0.048633687],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9539015,0.02248451,0.0109504815,0.001428945,0.00897184,0.002262727],"domain_scores_gemma":[0.9138905,0.0284113,0.008678845,0.0015081542,0.04337535,0.004135885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.046659447,0.0019375697,0.0027144896,0.0090688765,0.0020554946,0.0041654906,0.008127568,0.012017724,0.017109478],"category_scores_gemma":[0.09724802,0.0013476452,0.0061605433,0.0070627853,0.0019558968,0.004332995,0.0059974184,0.008235109,0.008996063],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000105883046,0.00016727565,0.0013943705,0.022361375,0.00020707636,0.00079939544,0.0032988903,0.0010342816,0.00032073073,0.014090787,0.60867465,0.3475453],"study_design_scores_gemma":[0.00019965832,0.00010319634,0.0023779168,0.08429041,0.00033965422,0.00071021786,0.0022006456,0.00032031312,0.000184249,0.010987478,0.8981988,0.00008748076],"about_ca_topic_score_codex":0.016229808,"about_ca_topic_score_gemma":0.015090258,"teacher_disagreement_score":0.046659447,"about_ca_system_score_codex":0.007426401,"about_ca_system_score_gemma":0.037785124,"threshold_uncertainty_score":0.24676174},"labels":[],"label_agreement":null},{"id":"W4285185611","doi":"10.1177/20406207221091046","title":"The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"AstraZeneca","keywords":"Paroxysmal nocturnal hemoglobinuria; Eculizumab; Medicine; Complement system; Complement component 5; Immunology; CD59; Complement (music); Internal medicine; Antibody","score_opus":0.05434598404694474,"score_gpt":0.36899612744775684,"score_spread":0.3146501434008121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285185611","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45726055,0.48938164,0.008445439,0.015708612,0.001831098,0.00008621082,0.0004197349,0.00017974322,0.026687037],"genre_scores_gemma":[0.95953685,0.03451334,0.0015249333,0.002198782,0.00078255334,0.000024469968,0.00017825139,0.000012325366,0.0012284542],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996749,0.00011355423,0.000030275625,0.00003877426,0.00009079653,0.00005171674],"domain_scores_gemma":[0.99953127,0.0001578469,0.0001232961,0.000022015009,0.00008869097,0.000076961456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005842786,0.00024161006,0.0003162011,0.0002970936,0.00022556554,0.00048548798,0.0002667758,0.0005440271,0.00074253936],"category_scores_gemma":[0.0016892023,0.00005859769,0.0002639727,0.00018132765,0.0004177152,0.0003206579,0.00025063942,0.0009352682,0.00013911883],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045237914,0.00049232855,0.13056307,0.002729628,0.0008792833,0.019402543,0.00067694404,0.0016531624,0.088461466,0.018582024,0.029273186,0.7027626],"study_design_scores_gemma":[0.0007771079,0.0034969924,0.43798915,0.003062558,0.0014583765,0.13726102,0.0009213017,0.009235154,0.063244306,0.034651283,0.30769536,0.00020743924],"about_ca_topic_score_codex":0.002264475,"about_ca_topic_score_gemma":0.0016953335,"teacher_disagreement_score":0.002264475,"about_ca_system_score_codex":0.0005699674,"about_ca_system_score_gemma":0.000558951,"threshold_uncertainty_score":0.004502654},"labels":[],"label_agreement":null},{"id":"W4295903721","doi":"10.1177/20406207221118429","title":"Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10 <sup>9</sup> /L to &lt;100 × 10 <sup>9</sup> /L) at baseline: the final analysis of EXPAND","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; AOP Orphan; Sierra Oncology; CTI Biopharma; Incyte; FibroGen; Gilead Sciences; BeiGene; Sanofi; MorphoSys; Celgene; AstraZeneca; Novartis; Pfizer; Amgen","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Adverse effect; Internal medicine; Clinical endpoint; Anemia; Phases of clinical research; Gastroenterology; Discontinuation; International Prognostic Scoring System; Clinical trial; Bone marrow; Myelodysplastic syndromes","score_opus":0.013257384808473436,"score_gpt":0.2773913357063457,"score_spread":0.2641339508978723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295903721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980926,0.0006765554,0.00010579109,0.0000746733,0.000004684226,0.00015227598,0.00030661485,0.000012195487,0.0005747145],"genre_scores_gemma":[0.9977399,0.000246605,0.00034238087,0.00014060311,0.00002295657,0.0001725341,0.001075462,0.0000030965048,0.00025649293],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995989,0.00018170266,0.00003122379,0.000068188754,0.00006404573,0.000055991346],"domain_scores_gemma":[0.9994349,0.00015620531,0.0001712523,0.000039448023,0.000043349977,0.00015485512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014128461,0.0005045759,0.0009711421,0.00026723684,0.00021629623,0.00042783978,0.00029141977,0.00038585076,0.0012835646],"category_scores_gemma":[0.0009791203,0.00021013859,0.00072799664,0.0002068309,0.00027756375,0.00048667414,0.00032225673,0.00074614707,0.00024630188],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5271119,0.010047575,0.2407935,0.00061744265,0.0022059185,0.0008621794,0.00042904328,0.0031629784,0.04242361,0.00030742417,0.004346212,0.16769224],"study_design_scores_gemma":[0.12578607,0.22849531,0.61874545,0.00013238275,0.0024459206,0.002160957,0.00018205841,0.00535481,0.010700876,0.00039661495,0.0055122753,0.000087298686],"about_ca_topic_score_codex":0.00034393882,"about_ca_topic_score_gemma":0.0013812477,"teacher_disagreement_score":0.0014128461,"about_ca_system_score_codex":0.0005155226,"about_ca_system_score_gemma":0.0006405453,"threshold_uncertainty_score":0.0074719787},"labels":[],"label_agreement":null},{"id":"W4381855175","doi":"10.1177/20406207231177282","title":"Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; National Cancer Institute; Galecto; Incyte; Servier; Celgene","keywords":"Medicine; Myelofibrosis; Essential thrombocythemia; Polycythemia vera; Bone marrow; Internal medicine; Myeloid leukemia; Myeloproliferative neoplasm; Oncology; Population; Myeloid; Acute leukemia; Haematopoiesis; Leukemia; Immunology; Stem cell","score_opus":0.17094447341793698,"score_gpt":0.44510187801768714,"score_spread":0.27415740459975013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381855175","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001364085,0.99836785,0.0000930952,0.000525108,0.00020172812,0.0000035077112,0.000016828024,0.000008859377,0.0006466619],"genre_scores_gemma":[0.0006338835,0.9983784,0.00015003321,0.00032098847,0.00021169496,0.0000046663563,0.000030227857,0.000001817366,0.00026831153],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99980766,0.00003943971,0.00003315391,0.000032205997,0.00006722671,0.000020410303],"domain_scores_gemma":[0.9995597,0.00021616362,0.000053758806,0.000011010406,0.00012564755,0.000033725657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055743224,0.0005790264,0.0010495785,0.0014098026,0.00024316121,0.0008204663,0.0007408589,0.0008490498,0.0031396106],"category_scores_gemma":[0.0009464262,0.00015737054,0.0004982425,0.0011988413,0.00031265427,0.0011227888,0.00053838314,0.0017556797,0.0013372597],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063741856,0.00007778359,0.00014021463,0.011733799,0.00006180671,0.00012252304,0.000044039567,0.0002944455,0.00081674743,0.0017404039,0.02855666,0.9563478],"study_design_scores_gemma":[0.000026731292,0.00017291962,0.000771167,0.0065383185,0.0001754102,0.0014132797,0.00007077986,0.00015882682,0.00035781748,0.0017415631,0.98855597,0.000017099983],"about_ca_topic_score_codex":0.0007034943,"about_ca_topic_score_gemma":0.0016170102,"teacher_disagreement_score":0.0031396106,"about_ca_system_score_codex":0.00046587203,"about_ca_system_score_gemma":0.0008250952,"threshold_uncertainty_score":0.010503054},"labels":[],"label_agreement":null},{"id":"W4386205570","doi":"10.1177/20406207231195594","title":"Luspatercept for transfusion-dependent β-thalassemia: time to get real","year":2023,"lang":"en","type":"editorial","venue":"Therapeutic Advances in Hematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"bluebird bio; Ionis Pharmaceuticals; La Jolla Pharmaceutical Company; Alexion Pharmaceuticals; Vertex Pharmaceuticals; Celgene; Sanofi; Amgen; Vifor Pharma; Pfizer; Agios Pharmaceuticals; Bristol-Myers Squibb","keywords":"Medicine; Thalassemia; Blood transfusion; Intensive care medicine; Internal medicine","score_opus":0.009589591266610426,"score_gpt":0.31268263054642265,"score_spread":0.30309303927981224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386205570","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000046797537,0.018638708,0.00015071564,0.033412144,0.9461355,0.000019996485,0.000038211212,0.000053344098,0.001504435],"genre_scores_gemma":[0.00042789715,0.010469434,0.00012507271,0.0292368,0.9548283,0.000020673882,0.00002609633,0.000025708803,0.004840052],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961527,0.0007980323,0.000528877,0.0003494482,0.0019008297,0.0002700082],"domain_scores_gemma":[0.9862299,0.0066732625,0.0008879911,0.00030104836,0.003767051,0.002140731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073366496,0.0029406939,0.0043886555,0.0021173793,0.0020863258,0.0062272176,0.003275412,0.015674114,0.008129175],"category_scores_gemma":[0.01713873,0.0009990562,0.0028074568,0.0012516386,0.001773774,0.003991899,0.0010858363,0.022177061,0.006557521],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094533214,0.000022781569,0.00002136148,0.00040875404,0.000042327003,0.000140093,0.0000088449515,0.000029952862,0.00007637346,0.0002789826,0.9881841,0.010691981],"study_design_scores_gemma":[0.00031024776,0.0001143448,0.00037606593,0.00093544,0.00020291531,0.0005054648,0.000037614285,0.00029760416,0.00017113847,0.0012435126,0.9957709,0.000034686687],"about_ca_topic_score_codex":0.0015194048,"about_ca_topic_score_gemma":0.0043879263,"teacher_disagreement_score":0.015674114,"about_ca_system_score_codex":0.0028281775,"about_ca_system_score_gemma":0.0023807837,"threshold_uncertainty_score":0.03880036},"labels":[],"label_agreement":null},{"id":"W4391890091","doi":"10.1177/20406207231218624","title":"The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Takeda Pharmaceuticals International; Grifols; Swedish Orphan Biovitrum; Baxalta; CSL Behring; Biogen; Novo Nordisk; Sanofi; Pfizer","keywords":"Medicine; Observational study; Interim analysis; Clinical endpoint; Adverse effect; Quality of life (healthcare); Internal medicine; Clinical trial; Pediatrics; Physical therapy","score_opus":0.016396079128889275,"score_gpt":0.3499241047546473,"score_spread":0.333528025625758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391890091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967899,0.001041979,0.000099170735,0.00010819761,0.000015312324,0.000057517376,0.0011544027,0.0000049622454,0.0007284742],"genre_scores_gemma":[0.9965738,0.00032414187,0.000105741485,0.0000893875,0.000039014845,0.000052159958,0.002578735,0.0000025583035,0.0002346689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984523,0.0005926127,0.00019577959,0.00019839063,0.00036654033,0.00019432089],"domain_scores_gemma":[0.9919258,0.0013911518,0.004238638,0.00056763645,0.00094723655,0.00092953705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043849987,0.00033244197,0.00089103595,0.00083236344,0.0005772342,0.0011106096,0.00036335498,0.0007622017,0.0010464834],"category_scores_gemma":[0.005450063,0.00016830415,0.0014123713,0.0008764518,0.00031727852,0.001056163,0.00072424265,0.0009867733,0.0003564617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013719197,0.0009176068,0.97280586,0.000073214804,0.00068305654,0.00010947692,0.000135016,0.00025989176,0.0002541136,0.000034247576,0.0005097502,0.010498589],"study_design_scores_gemma":[0.00056828547,0.0063315085,0.9906707,0.000025628282,0.00062665466,0.00017820898,0.00014094506,0.00041395277,0.00020581212,0.000040312683,0.00077461934,0.000023460709],"about_ca_topic_score_codex":0.0016384262,"about_ca_topic_score_gemma":0.0015497222,"teacher_disagreement_score":0.0043849987,"about_ca_system_score_codex":0.00053912314,"about_ca_system_score_gemma":0.00054696185,"threshold_uncertainty_score":0.02319032},"labels":[],"label_agreement":null},{"id":"W4402541521","doi":"10.1177/20406207241275376","title":"Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Ipsen; GlaxoSmithKline","keywords":"Medicine; Myeloid; Internal medicine; Oncology","score_opus":0.01123824306989505,"score_gpt":0.32939495014411596,"score_spread":0.3181567070742209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402541521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99491596,0.0011382744,0.000408196,0.00019566862,0.00003188718,0.0018147773,0.00067484373,0.000048291546,0.0007720372],"genre_scores_gemma":[0.99315876,0.0009343757,0.0012796432,0.00041846247,0.0000820127,0.0015770154,0.0015354824,0.000011786376,0.0010024683],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996973,0.00013331755,0.000024533747,0.000049708826,0.000038070215,0.00005707396],"domain_scores_gemma":[0.9994036,0.00008704773,0.0001722707,0.000042991593,0.000040693027,0.00025332783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013320785,0.0011178369,0.0012111749,0.00028625305,0.0003208221,0.0004879455,0.000467537,0.000546732,0.0032641122],"category_scores_gemma":[0.00079530274,0.00040086644,0.00056730706,0.0003323,0.0005954485,0.00051291846,0.0003032627,0.0018163449,0.00076468755],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58531713,0.09535779,0.039712664,0.0012108051,0.0012233475,0.001074784,0.00062653015,0.0038962942,0.122698486,0.0005040028,0.0075979736,0.14078009],"study_design_scores_gemma":[0.3790042,0.5663359,0.040352948,0.000046648638,0.00035449327,0.00096261705,0.00011790638,0.0014572871,0.0074508,0.00019896179,0.0036853142,0.00003292883],"about_ca_topic_score_codex":0.00044816284,"about_ca_topic_score_gemma":0.0013482178,"teacher_disagreement_score":0.0032641122,"about_ca_system_score_codex":0.0005951319,"about_ca_system_score_gemma":0.0013039154,"threshold_uncertainty_score":0.010919511},"labels":[],"label_agreement":null},{"id":"W4405416708","doi":"10.1177/20406207241298088","title":"Demographics, clinical characteristics, and real-world treatment patterns among patients with beta-thalassemia: a retrospective medical record abstraction study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Agios Pharmaceuticals; Vertex Pharmaceuticals; Sanofi; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Blood transfusion; Thalassemia; Internal medicine; Retrospective cohort study; Demographics; Anemia; Hemoglobin; Medical record; Pediatrics; Gastroenterology; Surgery; Demography","score_opus":0.01450649536129391,"score_gpt":0.33640647015400627,"score_spread":0.3218999747927124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405416708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980749,0.00017590413,0.00007991545,0.00003955581,0.0000023456178,0.000036626257,0.0013200683,0.0000046055097,0.00026608398],"genre_scores_gemma":[0.9983772,0.00012784742,0.00015144743,0.000045292632,0.0000065258687,0.00004322488,0.0011819421,0.0000021128042,0.00006435196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987025,0.00030107822,0.0003524005,0.00024064927,0.0002548666,0.00014842268],"domain_scores_gemma":[0.9950235,0.00093422766,0.002877311,0.00029962315,0.0004977228,0.00036767777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001199778,0.00018769914,0.00041634924,0.0018500728,0.00051794096,0.0006879233,0.0003864274,0.00039764162,0.0014040674],"category_scores_gemma":[0.004272036,0.00035528583,0.00039498508,0.002780585,0.00037408294,0.0010830082,0.00055596593,0.00054447167,0.0003114767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027928865,0.000019905949,0.9993513,0.000007781748,0.000010360778,0.000050897495,0.00009198213,0.000009836583,0.00003382359,0.0000045069955,0.0000590957,0.00033264433],"study_design_scores_gemma":[0.000008044394,0.000121437486,0.9980988,0.000014463611,0.000017439475,0.0006508451,0.0006341751,0.00012695628,0.000057063404,0.000008284536,0.00025706697,0.000005349929],"about_ca_topic_score_codex":0.0058299643,"about_ca_topic_score_gemma":0.00602206,"teacher_disagreement_score":0.0058299643,"about_ca_system_score_codex":0.0007363661,"about_ca_system_score_gemma":0.00065755966,"threshold_uncertainty_score":0.0115920305},"labels":[],"label_agreement":null},{"id":"W4412014975","doi":"10.1177/20406207251342199","title":"Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"AOP Orphan; Swedish Orphan Biovitrum; Novartis Pharma; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Celgene; Alexion Pharmaceuticals; Ariad Pharmaceuticals; Gilead Sciences; RWTH Aachen University; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Ruxolitinib; Phlebotomy; Internal medicine; Polycythemia vera; Thrombosis; Hematology; Retrospective cohort study; Myelofibrosis; Gastroenterology; Surgery; Bone marrow","score_opus":0.025718908178229527,"score_gpt":0.3605291126465878,"score_spread":0.3348102044683583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412014975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99969184,0.00011856753,0.000019197136,0.000010879316,0.0000028105283,0.0000073125643,0.00006270497,9.547842e-7,0.000085728614],"genre_scores_gemma":[0.999608,0.000045098106,0.000021804297,0.000024019453,0.000010328156,0.0000063273446,0.00024826234,4.8770585e-7,0.00003576524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999624,0.00012564054,0.000036938884,0.00010023913,0.0000581118,0.00005504943],"domain_scores_gemma":[0.99872404,0.00023570556,0.00053992093,0.0000815945,0.00007624668,0.00034252435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008432664,0.00025717876,0.0005356873,0.00035964354,0.00026955316,0.0006035198,0.00026070245,0.00047499483,0.0006984656],"category_scores_gemma":[0.0012971102,0.0001457198,0.00054866145,0.0004168043,0.0002726712,0.0004574727,0.00030257044,0.00044125313,0.00014417515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059756166,0.00040072485,0.9867582,0.000025208816,0.0003204645,0.00018427525,0.00008669668,0.00015177205,0.00087660435,0.00001814968,0.00017434206,0.00502805],"study_design_scores_gemma":[0.0008687628,0.004234989,0.9929512,0.0000103290295,0.00021593542,0.0006127273,0.000115044575,0.00048408817,0.00025433826,0.00003672038,0.00020454808,0.000011345172],"about_ca_topic_score_codex":0.0005391995,"about_ca_topic_score_gemma":0.00076962623,"teacher_disagreement_score":0.0008432664,"about_ca_system_score_codex":0.00041245393,"about_ca_system_score_gemma":0.00020277456,"threshold_uncertainty_score":0.004459679},"labels":[],"label_agreement":null},{"id":"W4415458924","doi":"10.1177/20406207251388051","title":"Immunoglobulin treatment and clinical outcomes: data from the Ontario Immunoglobulin Treatment program multicenter case registry","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University of Ottawa; Sault Area Hospital; Public Health Ontario; University of Toronto; Ottawa Hospital","funders":"Ontario Ministry of Health and Long-Term Care","keywords":"Antibody; Clinical trial; Antibody therapy; Health care; Multicenter study; Healthcare system; MEDLINE","score_opus":0.06523791734071023,"score_gpt":0.4231188872636341,"score_spread":0.3578809699229239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415458924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97518325,0.0005634752,0.00019452235,0.0002465027,0.0000060832917,0.00021118825,0.020613119,0.000021197611,0.002960739],"genre_scores_gemma":[0.9823714,0.0005747653,0.0003045019,0.00009603506,0.000013806034,0.0002140078,0.01605259,0.000008966041,0.00036379969],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688476,0.00035563696,0.00038279052,0.00038314224,0.0014226516,0.0005710027],"domain_scores_gemma":[0.99064344,0.0006843826,0.0052255085,0.00056679203,0.002047127,0.0008327002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018685696,0.00024317559,0.0004511506,0.0023383508,0.0010138352,0.0008983048,0.0011463861,0.0003573944,0.0015899295],"category_scores_gemma":[0.0070538926,0.0003041339,0.00038476844,0.007391617,0.0005389081,0.00052606047,0.00092611474,0.00034947408,0.0003108416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055214823,0.000015063326,0.9970673,0.00002280983,0.000024148429,0.00006445504,0.00015269847,0.000028466995,0.000045662076,0.000021220138,0.0011865136,0.0013164405],"study_design_scores_gemma":[0.000011409494,0.000014873776,0.9989808,0.00001675963,0.00001595935,0.00008313557,0.000170433,0.00007254907,0.00001757904,0.000006536107,0.0006063818,0.0000035470039],"about_ca_topic_score_codex":0.71507716,"about_ca_topic_score_gemma":0.78464025,"teacher_disagreement_score":0.71507716,"about_ca_system_score_codex":0.008710359,"about_ca_system_score_gemma":0.011386234,"threshold_uncertainty_score":0.5732016},"labels":[],"label_agreement":null},{"id":"W7116052349","doi":"10.1177/20406207251401313","title":"The efficacy and safety of anti-CD20 antibody for the treatment of B-ALL: a systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meta-analysis; Clinical trial; Adverse effect; Antibody; Systematic review; Randomized controlled trial; MEDLINE","score_opus":0.04353487925067105,"score_gpt":0.41296347622671764,"score_spread":0.3694285969760466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116052349","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029734517,0.99525684,0.0005311823,0.00018386368,0.00012632489,0.00034282613,0.0003696487,0.00002227932,0.00019353851],"genre_scores_gemma":[0.09302704,0.9012659,0.0023977926,0.00074815133,0.0002545823,0.0012978313,0.00069976534,0.000028983259,0.00027998583],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9892777,0.004843209,0.003275806,0.00093165773,0.0013632104,0.00030850642],"domain_scores_gemma":[0.98420185,0.01134789,0.0023828496,0.0004935957,0.0013695611,0.00020425247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015474555,0.0033330824,0.02226855,0.00951589,0.00070884643,0.0035270066,0.0022261685,0.0023397028,0.0031575328],"category_scores_gemma":[0.028655522,0.001689853,0.046123818,0.009170073,0.0007928496,0.002129069,0.0017109907,0.0019559965,0.000320849],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013068586,0.000024582547,0.0017488227,0.4444303,0.54016286,0.00011170785,0.00007417477,0.00053016766,0.0002324666,0.00013516044,0.00046262227,0.010780382],"study_design_scores_gemma":[0.0003459545,0.00012623693,0.0014535332,0.023277078,0.97312534,0.00007361909,0.000030135143,0.00015402958,0.000097185635,0.00013715531,0.0011609617,0.000018770728],"about_ca_topic_score_codex":0.00612728,"about_ca_topic_score_gemma":0.012828248,"teacher_disagreement_score":0.02226855,"about_ca_system_score_codex":0.0032785097,"about_ca_system_score_gemma":0.004473238,"threshold_uncertainty_score":0.08183825},"labels":[],"label_agreement":null}]}